en · de · es · fr · pt
aod-9604-notes.peptides3626.com › Guide › Research And Regulatory Status — 2026 Update

Research And Regulatory Status — 2026 Update

By Editorial Desk · published 2026-07-15 · last reviewed 2026-08-01 · Guide

If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Research and Regulatory Status

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Aod-9604 at a glance

PropertyValueNotes
Primary research areaObesity and metabolic regulationStudied in cell, animal, and human models
Highest reported trial phasePhase IIPublic summaries describe mixed results
Common route in trialsSubcutaneous injectionTypical for peptide therapeutics
Regulatory example2013 Australian anti-doping reviewClassification was debated at the time
Approval statusNot approved as a human medicineStatus can change by jurisdiction

Further detail

== Further reading == Tracy, Will W. Tomato culture: A practical treatise on the tomato: (1907) online primary source on expert knowledge in early 20th century David Gentilcore. Pomodoro! A History of the Tomato in Italy (Columbia University Press, 2010), scholarly history Tieman, D.; Bliss, P.; McIntyre, L.M.; Blandon-Ubeda, A.; Bies, D.; Odabasi, A.Z.; Rodríguez, G.R.; van der Knaap, E; Taylor, M.G.; Goulet, C.; Mageroy, M.H.; Snyder, D.J.; Colquhoun, T.; Moskowitz, H.; Clark, D.G.; Sims, C.; Bartoshuk, L.; Klee, H.J. (5 June 2012). "The Chemical Interactions Underlying Tomato Flavor Preferences". Current Biology. 22 (11): 1035–1039. Bibcode:2012CBio...22.1035T. doi:10.1016/j.cub.2012.04.016. PMID 22633806.

== Definition == The shutdown margin for nuclear reactors (that is, when the reactor is considered to be safely in a shutdown state) is usually defined either in terms of reactivity or dollars. For reactivity, this is calculated in units of delta-k/k, where k is equal to the criticality of the reactor (essentially, how fast and controlled the nuclear fission reaction is). It is sometimes also measured in dollars, where one dollar is equal to a reactor in prompt criticality, this can then be used to calculate the change in reactivity required to shut down or start up the reactor. The shutdown margin for each reactor can either refer to the margin by which a reactor is subcritical with all its control rods inserted, or as the margin by which the reactor would be shut down in the event of a SCRAM. This margin has to be considered carefully for each reactor and reactor design, to ensure that it remains within the technical specifications and limitations of the reactor.

==== Panicogenic ==== The CCK tetrapeptide fragment CCK-4 (Trp-Met-Asp-Phe-NH2) reliably causes anxiety and panic attacks (panicogenic effect) when administered to humans and is commonly used in scientific research in order to test new anxiolytic drugs. Positron emission tomography visualization of regional cerebral blood flow in patients undergoing CCK-4 induced panic attacks show changes in the anterior cingulate gyrus, the claustrum-insular-amygdala region, and cerebellar vermis.

Sources: en.wikipedia.org

Related pages on this site

Background from the literature

=== Storage === Dependent on the storage conditions, garlic powder generally lasts in good condition up to 4 years. Manufactured garlic powders have a 'best before' date printed on them to provide an estimate for how long the powder will be in peak condition for in respect to flavor and texture. Garlic powder must be stored in a cool, dry place, to avoid clumping of the powder. If powder is exposed to moisture or heat, it could cause the product to harden or clump.

EC 2.4.2.24: 1,4-β-D-xylan synthase EC 2.4.2.25: flavone apiosyltransferase EC 2.4.2.26: protein xylosyltransferase EC 2.4.2.27: dTDP-dihydrostreptose—streptidine-6-phosphate dihydrostreptosyltransferase EC 2.4.2.28: S-methyl-5′-thioadenosine phosphorylase EC 2.4.2.29: tRNA-guanosine34 preQ1 transglycosylase EC 2.4.2.30: NAD+ ADP-ribosyltransferase EC 2.4.2.31: NAD+—protein-arginine ADP-ribosyltransferase EC 2.4.2.32: dolichyl-phosphate D-xylosyltransferase EC 2.4.2.33: dolichyl-xylosyl-phosphate—protein xylosyltransferase EC 2.4.2.34: indolylacetylinositol arabinosyltransferase EC 2.4.2.35: flavonol-3-O-glycoside xylosyltransferase EC 2.4.2.36: NAD+—diphthamide ADP-ribosyltransferase EC 2.4.2.37: NAD+ —dinitrogen-reductase ADP-D-ribosyltransferase EC 2.4.2.38: glycoprotein 2-β-D-xylosyltransferase EC 2.4.2.39: xyloglucan 6-xylosyltransferase EC 2.4.2.40: zeatin O-β-D-xylosyltransferase EC 2.4.2.41: xylogalacturonan β-1,3-xylosyltransferase EC 2.4.2.42: UDP-D-xylose:β-D-glucoside α-1,3-D-xylosyltransferase EC 2.4.2.43: lipid IVA 4-amino-4-deoxy-L-arabinosyltransferase EC 2.4.2.44: S-methyl-5′-thioinosine phosphorylase EC 2.4.2.45: decaprenyl-phosphate phosphoribosyltransferase EC 2.4.2.46: galactan 5-O-arabinofuranosyltransferase EC 2.4.2.47: arabinofuranan 3-O-arabinosyltransferase EC 2.4.2.48: tRNA-guanine15 transglycosylase EC 2.4.2.49: neamine phosphoribosyltransferase EC 2.4.2.50: cyanidin 3-O-galactoside 2′′-O-xylosyltransferase EC 2.4.2.51: anthocyanidin 3-O-glucoside 2′′′-O-xylosyltransferase EC 2.4.2.52: triphosphoribosyl-dephospho-CoA synthase EC 2.4.2.53: undecaprenyl-phosphate 4-deoxy-4-formamido-L-arabinose transferase EC 2.4.2.54: β-ribofuranosylphenol 5′-phosphate synthase EC 2.4.2.55: nicotinate D-ribonucleotide:phenol phospho-D-ribosyltransferase EC 2.4.2.56: kaempferol 3-O-xylosyltransferase EC 2.4.2.57: AMP phosphorylase EC 2.4.2.58: hydroxyproline O-arabinosyltransferase EC 2.4.2.59: sulfide-dependent adenosine diphosphate thiazole synthase EC 2.4.2.60: cysteine-dependent adenosine diphosphate thiazole synthase EC 2.4.2.61: α-dystroglycan β1,4-xylosyltransferase EC 2.4.2.62: xylosyl α-1,3-xylosyltransferase EC 2.4.2.63: EGF-domain serine xylosyltransferase EC 2.4.2.64: tRNA-guanosine34 queuine transglycosylase

However, as Liebling began to make his first attempts at recovery, the filmmakers started to see potential in his journey. Shaping Last Days Here into a coherent narrative proved to be a challenge. Liebling's personality was more erratic than the documentary ultimately portrayed. "Many times we had to finesse the rapid shifts in Bobby's life so the viewer wouldn't be left confused. Over the three years we were shooting, we saw the many different faces of Bobby Liebling. The delusional crack-smoking hustler, the arrogant '70s rock star, and the really cool loveable uncle. When boiling the footage down to 90 minutes, we really wanted to exemplify a balance of those personalities. That balance is sometimes tough to maintain," stated Fenton.

Sources: en.wikipedia.org

Frequently asked questions

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Why is AOD-9604 discussed in anti-doping?

It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.

What did human trials of AOD-9604 find?

Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.

What is AOD-9604?

It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.

Network